Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2018 | Isatuximab: a ‘next-generation monoclonal antibody’

Speaking from the 23rd Congress of the European Hematology Association (EHA) 2018, held in Stockholm, Sweden, Paul Richardson, MD, of the Dana-Farber Cancer Institute, Boston, MA, tells us about isatuximab, a revolutionary new antibody that has already been making waves in the multiple myeloma (MM) field. Dr Richardson explains why this antibody has been dubbed ‘next-generation’, despite being developed at the same time as many others, including daratumumab, before mentioning ICARIA-MM (NCT02990338), a trial aimed at determining the effects of isatuximab in combination with pomalidomide and dexamethasone.